To determine and compare how Dasatinib/Torin-2 (D+T) or Dasatinib/Rapamycin (D+R) combination treatment affects the mTOR signaling pathway, we analyzed the phosphorylation status of downstream targets of mTORC1 (4E-BP, Ser65 and ribosomal protein kinase S6, Thr389) and mTORC2 (AKT, Ser473), as well as AKT phosphorylation at Thr308 by PDK-1, a kinase activated by PI3K signaling 31 in NB cell lines Kelly and IMR-32 6 and 24 h after treatment using immunoblot analysis. Here, AKT1 is linked to neuroblastoma.